News
RVNC
--
0.00%
--
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of defensives such as healthcare stocks.
Benzinga · 23h ago
Non-Surgical Cosmetic Treatment Market Emerging Size 2021 Report Covers Top Countries Data, Regional Analysi, Top Key Players, Development Status, Global Industry Share Forecast to 2027
Apr 09, 2021 (The Expresswire) -- Global "Non-Surgical Cosmetic Treatment Market" Research Report features an extensive study of the current market landscape...
The Express Wire · 2d ago
Botulinum Toxin Fillers Market 2021 is Booming by Leading key Players - Forecast 2026 | Allergan PLC, Medytoc Solutions Inc, Ipsen, Merz Pharma Gmbh
Market Insight Reports · 4d ago
Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 20th Annual Needham Virtual Healthcare Conference, a fully virtual manage...
BusinessWire · 4d ago
Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting
Revance Therapeutics (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the company will present an ePoster at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting taking place ...
BusinessWire · 04/01 12:00
Cramer's lightning round: You should own PayPal, don't trade it
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 03/26 23:27
Non-Surgical Rejuvenation Market Is Anticipated To Register Around 8.20% CAGR From 2020 To 2026
Mar 26, 2021 (Market Insight Reports) -- The Non-Surgical Rejuvenation Market size is forecast to reach $9.10 billion by 2026, growing at a CAGR of 8.20%...
Market Insight Reports · 03/26 10:55
Botulinum Toxin Fillers Market Global Industry Insights, Trends, Size, Share, Outlook, And Opportunity Analysis, 2020-2027 By Ameco Research
pune, India, Thu, 25 Mar 2021 03:24:59 / Comserve Inc. / -- The global Botulinum Toxin Fillers market is segmented by company, region (country), by Type, and...
Comserve · 03/25 07:27
Botulinum Toxin and HA Dermal Filler Market Size Research Report 2021 by Trade Statistics, Type, Application, Company Profiles and Forecast to 2025
Mar 24, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Botulinum Toxin is a poisonous natural...
The Express Wire · 03/24 12:59
Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021
Business Wire · 03/22 21:05
Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021
Fortune Designates Revance as the Top 10 Best Workplaces in Biopharma in 2021
Business Wire · 03/22 21:05
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength?
Zacks.com · 03/22 20:19
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength?
Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks · 03/22 15:05
Investors Who Bought Revance Therapeutics (NASDAQ:RVNC) Shares A Year Ago Are Now Up 73%
Diversification is a key tool for dealing with stock price volatility. Of course, the aim of the game is to pick stocks...
Simply Wall St. · 03/12 09:06
Botulinum Toxin Fillers Market 2021 Share, Top Manufacturers, Botulinum Toxin Fillers Market Size, Segmentation, Types, Application, Technology, Trends and Forecasts to 2026
Mar 11, 2021 (The Expresswire) -- Global “Botulinum Toxin Fillers Market” (2021-2026) to its vast repository and growth prospects of the market provides the...
The Express Wire · 03/12 03:30
Botulinum Neurotoxins Market SWOT Analysis by Key Players- Merz Pharma, Allergan, Ipsen
Mar 10, 2021 (Market Insight Reports) -- The research emphasizes elaboration of the Global Botulinum Neurotoxins market strategy of the industry players in...
Market Insight Reports · 03/10 13:25
Facial Injectors Market Share, Size Global Manufactures, Consumption, Drivers, Top Leading Countries, Trends,Growth Factors, Forces Analysis, Revenue, Challenges and Global Forecast to 2023
Mar 10, 2021 (The Expresswire) -- Global Facial Injectors Market Research Report presents competitive environment such as key competitors, key trends,...
The Express Wire · 03/10 05:37
MiMedx Announces Appointment of Phyllis Gardner, M.D. to Board of Directors
MARIETTA, Mar 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- Noted biopharmaceutical thought leader adds academic, research and industry expertise MARIETTA, Ga.,...
GlobeNewswire · 03/08 22:34
Dermal Fillers Market Size worth USD 6.64 Billion by 2027 at 9.3% CAGR; High Demand for Minimally Invasive Surgeries to Boost Growth: Fortune Business Insights(TM)
The global dermal fillers market is set to gain traction from the increasing usage of hyaluronic acid dermal fillers as they are considered to be the gold standard material for facial fillers, such as restoration of volume/fullness, scar treatment, lip enh...
GlobeNewswire · 03/03 11:34
10-K: REVANCE THERAPEUTICS, INC.
Edgar Online - (EDG = 10Q, 10K) · 02/25 21:58
Webull provides a variety of real-time RVNC stock news. You can receive the latest news about Revance through multiple platforms. This information may help you make smarter investment decisions.
About RVNC
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.